Carvacrol ameliorates cyclophosphamide-induced rat premature ovarian failure and uterine fibrosis via regulating PI3K/AKT/FOXO3a signaling pathway.

ABSTRACT:

Background

Premature ovarian failure (POF) and ovarian reserve loss are common problems associated with cancer therapies. Carvacrol (Carva) showed significant efficacies in ameliorating several toxicological impacts and complications associated with chemotherapeutic agents. Thus, this study was established to speculate on the efficacy of Carva against cyclophosphamide (Cyclo)-provoked POF.

Methods

A twenty-four mature female rats were randomly and equally allocated into four groups; normal group, Carva (15 mg/kg/day/orally/3 weeks) group, Cyclo (75 mg/kg/i.p/once weekly/3 weeks) group, and Carva + Cyclo group. Assessments of serum sex hormones, as well as ovarian oxidative stress-related pathways, along with histopathological alterations in ovary and uterine tissues, have be

SUBMITTER: El-Gendy ZA 

PROVIDER: S-EPMC12687504 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature